{
  "version": "GOLD 2026",
  "last_updated": "2026-01-14",
  "classification_system": {
    "name": "GOLD ABE System",
    "description": "Simplified classification based on symptoms and exacerbation risk",
    "groups": {
      "A": {
        "name": "Less Symptomatic, Low Risk",
        "criteria": {
          "symptoms": {
            "mMRC": "0-1",
            "CAT": "<10"
          },
          "exacerbations": {
            "count": 0,
            "hospitalization": false
          }
        },
        "treatment_strategy": "Single long-acting bronchodilator (LAMA or LABA)",
        "first_line": [
          {
            "class": "LAMA",
            "rationale": "Preferred due to slightly better exacerbation protection",
            "options": [
              "Tiotropium 18 mcg once daily (DPI) or 2.5 mcg 2 inhalations once daily (SMI)",
              "Aclidinium 400 mcg twice daily",
              "Umeclidinium 62.5 mcg once daily",
              "Glycopyrrolate 50 mcg once daily"
            ]
          },
          {
            "class": "LABA",
            "rationale": "Alternative if LAMA not tolerated or contraindicated",
            "options": [
              "Salmeterol 50 mcg twice daily",
              "Formoterol 20 mcg twice daily",
              "Indacaterol 75-150 mcg once daily",
              "Olodaterol 2.5 mcg (2 inhalations) once daily"
            ]
          }
        ],
        "alternative": [
          "Short-acting bronchodilators only for very mild, intermittent symptoms"
        ]
      },
      "B": {
        "name": "More Symptomatic, Low Risk",
        "criteria": {
          "symptoms": {
            "mMRC": "≥2",
            "CAT": "≥10"
          },
          "exacerbations": {
            "count": 0,
            "hospitalization": false
          }
        },
        "treatment_strategy": "Dual bronchodilator therapy (LAMA-LABA)",
        "first_line": [
          {
            "class": "LAMA-LABA Combination",
            "rationale": "Superior symptom control and lung function improvement",
            "options": [
              "Tiotropium-Olodaterol 2.5/2.5 mcg, 2 inhalations once daily (SMI)",
              "Umeclidinium-Vilanterol 62.5/25 mcg, 1 inhalation once daily (DPI)",
              "Glycopyrronium-Indacaterol 50/110 mcg once daily (DPI)",
              "Glycopyrrolate-Formoterol 9/4.8 mcg, 2 inhalations twice daily (MDI)",
              "Aclidinium-Formoterol 400/12 mcg once daily (DPI)"
            ]
          }
        ],
        "alternative": [
          "Single long-acting bronchodilator (LAMA preferred over LABA) if dual therapy not available or tolerated"
        ],
        "special_considerations": [
          {
            "condition": "Asthma-COPD overlap",
            "recommendation": "Consider adding ICS to LAMA-LABA therapy"
          }
        ]
      },
      "E": {
        "name": "High Risk of Exacerbations",
        "criteria": {
          "exacerbations": {
            "count": "≥1 moderate or severe",
            "definition": "Requiring systemic antibiotics/glucocorticoids or hospitalization"
          }
        },
        "treatment_strategy": "LAMA-LABA (may escalate to triple therapy based on eosinophils)",
        "first_line": [
          {
            "class": "LAMA-LABA Combination",
            "rationale": "Reduces exacerbations with lower pneumonia risk than ICS-containing regimens",
            "options": [
              "Tiotropium-Olodaterol 2.5/2.5 mcg, 2 inhalations once daily (SMI)",
              "Umeclidinium-Vilanterol 62.5/25 mcg, 1 inhalation once daily (DPI)",
              "Glycopyrronium-Indacaterol 50/110 mcg once daily (DPI)",
              "Glycopyrrolate-Formoterol 9/4.8 mcg, 2 inhalations twice daily (MDI)",
              "Aclidinium-Formoterol 400/12 mcg once daily (DPI)"
            ]
          }
        ],
        "eosinophil_guided_therapy": {
          "high_eosinophils": {
            "threshold": "≥300 cells/μL",
            "recommendation": "Consider triple therapy (LAMA-LABA-ICS) upfront",
            "rationale": "Greater ICS benefit, reduced exacerbation risk",
            "options": [
              "LAMA + LABA-ICS combination",
              "Single-inhaler triple therapy if available"
            ]
          },
          "intermediate_eosinophils": {
            "threshold": "100-299 cells/μL",
            "recommendation": "Start LAMA-LABA, consider adding ICS if frequent exacerbations persist",
            "rationale": "Moderate ICS benefit"
          },
          "low_eosinophils": {
            "threshold": "<100 cells/μL",
            "recommendation": "Avoid ICS if possible",
            "rationale": "Minimal ICS benefit, increased pneumonia risk"
          }
        },
        "special_considerations": [
          {
            "condition": "Recent hospitalization for exacerbation",
            "recommendation": "Consider triple therapy (LAMA-LABA-ICS) regardless of eosinophil count"
          },
          {
            "condition": "≥2 moderate exacerbations or ≥1 hospitalization per year",
            "recommendation": "Strong consideration for triple therapy"
          },
          {
            "condition": "Asthma-COPD overlap",
            "recommendation": "Triple therapy (LAMA-LABA-ICS) preferred"
          }
        ]
      }
    }
  },
  "rescue_therapy": {
    "indication": "All patients should have rescue bronchodilator for symptom relief",
    "options": {
      "patients_on_LAMA": [
        {
          "medication": "Albuterol (SABA)",
          "dose": "90 mcg, 2 puffs as needed",
          "notes": "Preferred for most patients on LAMA therapy"
        },
        {
          "medication": "Levalbuterol (SABA)",
          "dose": "45 mcg, 2 puffs as needed",
          "notes": "Alternative SABA"
        }
      ],
      "patients_not_on_LAMA": [
        {
          "medication": "Ipratropium-Albuterol (SAMA-SABA)",
          "dose": "20/100 mcg, 1 inhalation every 4-6 hours as needed",
          "notes": "Preferred combination for enhanced bronchodilation"
        }
      ]
    },
    "cautions": [
      "Avoid regular scheduled use of SABA",
      "Frequent SABA use (>2 times per week) indicates need for long-acting therapy",
      "Monitor for side effects: tremor, tachycardia, hypokalemia"
    ]
  },
  "spirometry_classification": {
    "GOLD_1": {
      "FEV1_percent_predicted": "≥80%",
      "severity": "Mild airflow limitation",
      "notes": "May be asymptomatic or have minimal symptoms"
    },
    "GOLD_2": {
      "FEV1_percent_predicted": "50-79%",
      "severity": "Moderate airflow limitation",
      "notes": "Usually seek medical attention due to symptoms"
    },
    "GOLD_3": {
      "FEV1_percent_predicted": "30-49%",
      "severity": "Severe airflow limitation",
      "notes": "Significant impact on quality of life"
    },
    "GOLD_4": {
      "FEV1_percent_predicted": "<30%",
      "severity": "Very severe airflow limitation",
      "notes": "Life-threatening; may require oxygen therapy"
    }
  },
  "non_pharmacologic_management": {
    "essential_interventions": [
      {
        "intervention": "Smoking cessation",
        "priority": "Highest",
        "notes": "Single most effective intervention to slow disease progression"
      },
      {
        "intervention": "Pulmonary rehabilitation",
        "priority": "High",
        "notes": "Improves symptoms, exercise capacity, and quality of life"
      },
      {
        "intervention": "Vaccinations",
        "priority": "High",
        "vaccines": [
          "Influenza (annual)",
          "Pneumococcal (PCV20 or PCV15 + PPSV23)",
          "COVID-19",
          "Respiratory syncytial virus (RSV) for adults ≥60 years"
        ]
      }
    ],
    "additional_interventions": [
      "Regular physical activity and exercise training",
      "Nutritional assessment and optimization",
      "Oxygen therapy if resting SpO2 ≤88% or PaO2 ≤55 mmHg",
      "Education on inhaler technique",
      "Self-management education and action plans",
      "Psychosocial support"
    ]
  },
  "adverse_effects": {
    "LABA": [
      "Tremor",
      "Tachycardia",
      "Palpitations",
      "Hypokalemia (with high doses)",
      "Rarely: arrhythmias"
    ],
    "LAMA": [
      "Dry mouth (most common)",
      "Urinary retention (especially in patients with BPH)",
      "Narrow-angle glaucoma exacerbation",
      "Constipation"
    ],
    "ICS": [
      "Pneumonia (increased risk)",
      "Oropharyngeal candidiasis",
      "Dysphonia",
      "Skin bruising",
      "Cataracts (long-term use)",
      "Osteoporosis risk (high doses, long-term)"
    ]
  },
  "follow_up": {
    "initial_visit": "2-4 weeks after starting new therapy",
    "stable_patients": "Every 3-6 months",
    "monitoring_parameters": [
      "Symptom control (mMRC, CAT score)",
      "Exacerbation frequency and severity",
      "Medication adherence and inhaler technique",
      "Adverse effects",
      "Spirometry (annually or as needed)",
      "Oxygen saturation",
      "Comorbidities",
      "Smoking status"
    ],
    "therapy_adjustment": {
      "insufficient_symptom_control": "Escalate therapy (add bronchodilator or ICS)",
      "persistent_exacerbations": "Consider triple therapy, roflumilast, or macrolide",
      "side_effects": "Switch to alternative agent or reduce dose",
      "well_controlled": "Continue current therapy"
    }
  },
  "referral_criteria": {
    "pulmonology": [
      "Diagnostic uncertainty",
      "Severe COPD (GOLD 3-4)",
      "Frequent exacerbations despite optimal therapy",
      "Rapid decline in lung function",
      "Hemoptysis",
      "Consideration for oxygen therapy",
      "Consideration for lung volume reduction or transplant"
    ],
    "pulmonary_rehabilitation": [
      "All symptomatic patients with COPD",
      "Especially those with functional limitations"
    ]
  }
}
